Bank of Montreal
ABEO icon

Bank of Montreal’s Abeona Therapeutics ABEO Stock Holding History

Bank of Montreal’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-400
Closed -$144K – 4693
2018
Q1 		$144K Sell
400
-572
-59% -$213K ﹤0.01% 2790
2017
Q4 		$385K Buy
+972
New +$402K ﹤0.01% 2400

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of Montreal's ABEO Position: Q4 2024 in Review

Bank of Montreal sold out of Abeona Therapeutics (ABEO) in Q4 2024, closing a stake of 14,300 shares — an estimated $84.8K sold.

Bank of Montreal first reported a position in ABEO in Q4 2017 and held it in 14 quarters. The position peaked at $385K in Q4 2017. 65 funds tracked by Wall St. Rank hold ABEO as of Q4 2024.

  • Bank of Montreal reported no remaining Abeona Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bank of Montreal sold 14,300 Abeona Therapeutics shares in Q4 2024, an estimated $84.8K.
  • Bank of Montreal first reported a position in Abeona Therapeutics in Q4 2017 and held it in 14 quarters.
  • Bank of Montreal's Abeona Therapeutics position peaked at $385K in Q4 2017.
  • 65 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2024.

Based on Bank of Montreal's 13F filing for Q4 2024, filed 13 Feb 2025.